Seeking Alpha

Three partners in the development of diabetes drug Bydureon - Amylin (AMLN), Alkermes (ALKS) and...

Three partners in the development of diabetes drug Bydureon - Amylin (AMLN), Alkermes (ALKS) and Eli Lilly (LLY) - say the treatment didn’t slow heart rate in further testing requested last year by the FDA. ALKS +1.4%, AMLN +6.9%, LLY -0.7% premarket. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|